HC Wainwright Reiterates “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 38.04% from the stock’s current price.

A number of other research firms have also commented on DYN. Piper Sandler upped their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Chardan Capital upped their price target on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the company a “buy” rating in a report on Friday, March 8th. Morgan Stanley began coverage on shares of Dyne Therapeutics in a report on Tuesday. They set an “overweight” rating and a $40.00 price target for the company. Raymond James upped their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a report on Thursday, January 4th. Finally, Oppenheimer reiterated an “outperform” rating and set a $47.00 price target on shares of Dyne Therapeutics in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.75.

Dyne Therapeutics Trading Up 0.3 %

Shares of DYN traded up $0.08 during mid-day trading on Friday, reaching $26.08. The company’s stock had a trading volume of 761,928 shares, compared to its average volume of 1,882,175. The stock has a market cap of $2.25 billion, a PE ratio of -6.62 and a beta of 1.00. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $30.27. The company’s fifty day moving average price is $26.34 and its two-hundred day moving average price is $18.29.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Research analysts anticipate that Dyne Therapeutics will post -3.27 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Joshua T. Brumm sold 5,520 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $151,800.00. Following the completion of the transaction, the chief executive officer now directly owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $22.57, for a total value of $4,164,187.57. Following the completion of the transaction, the insider now directly owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Joshua T. Brumm sold 5,520 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $27.50, for a total transaction of $151,800.00. Following the completion of the transaction, the chief executive officer now owns 563,471 shares of the company’s stock, valued at $15,495,452.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,875,432 shares of company stock worth $44,368,530. 20.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently bought and sold shares of the company. Jennison Associates LLC grew its position in Dyne Therapeutics by 495.2% during the 1st quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after purchasing an additional 1,004,680 shares during the last quarter. Capstone Investment Advisors LLC purchased a new stake in Dyne Therapeutics during the 1st quarter valued at about $575,000. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 24.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company’s stock valued at $812,000 after purchasing an additional 5,696 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 119.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,573 shares of the company’s stock valued at $442,000 after acquiring an additional 8,474 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.